Eupraxia Pharmaceuticals Files 6-K Report

Ticker: EPRX · Form: 6-K · Filed: Sep 29, 2025 · CIK: 1581178

Sentiment: neutral

Topics: material-change, foreign-private-issuer, regulatory-filing

Related Tickers: EPRX

TL;DR

Eupraxia Pharma (EPRX) filed a 6-K on 9/29, reporting a material change from 9/25. Check for details.

AI Summary

Eupraxia Pharmaceuticals Inc. filed a Form 6-K on September 29, 2025, reporting a Material Change dated September 25, 2025. The company is based in Victoria, British Columbia, Canada, and its Chief Financial Officer, Alex Rothwell, signed the report.

Why It Matters

This filing indicates a significant update or change within Eupraxia Pharmaceuticals, which could impact investors' understanding of the company's current status and future prospects.

Risk Assessment

Risk Level: medium — Form 6-K filings often contain material updates that can significantly impact a company's stock price, requiring careful investor attention.

Key Numbers

Key Players & Entities

FAQ

What specific material change is reported in Exhibit 99.1?

The filing does not detail the specific content of Exhibit 99.1, only that it is a Material Change Report dated September 25, 2025.

What is the primary purpose of a Form 6-K filing?

A Form 6-K is used by foreign private issuers to report information that they have made or are required to make public in their home country, or that they have distributed or are required to distribute to their security holders.

Where is Eupraxia Pharmaceuticals Inc. located?

Eupraxia Pharmaceuticals Inc. is located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada.

Who signed the Form 6-K on behalf of Eupraxia Pharmaceuticals Inc.?

Alex Rothwell, Chief Financial Officer, signed the Form 6-K.

What is the SIC code for Eupraxia Pharmaceuticals Inc.?

The Standard Industrial Classification (SIC) code for Eupraxia Pharmaceuticals Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 155 words · 1 min read · ~1 pages · Grade level 12.7 · Accepted 2025-09-29 16:32:49

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc. (Registrant) Date: September 29, 2025 /s/ Alex Rothwell Alex Rothwell Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing